Key result
DIBH-3DCRT and FB-HT significantly reduced the radiation dose to the heart, left anterior descending coronary artery, and ventricles compared to FB-3DCRT.
Why the study?
Mean heart dose is not a sufficient dosimetric parameter for assessing cardiac exposure during left-sided breast cancer radiotherapy, motivating evaluation of radiation exposure to cardiac substructures across different techniques.
Does DIBH-3DCRT or FB-HT reduce radiation exposure to cardiac substructures compared to FB-3DCRT in patients with left-sided breast cancer?
Does DIBH-3DCRT or FB-HT reduce radiation exposure to cardiac substructures compared to FB-3DCRT in patients with left-sided breast cancer?
DIBH-3DCRT and FB-HT significantly reduce radiation dose to major coronary vessels and ventricles compared to FB-3DCRT in left-sided breast cancer patients, which may help mitigate late cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
May lower late cardiotoxicity risk with DIBH-3DCRT or FB-HT in left breast RT; leaves open translation to clinical events.
Eber et al. (2023) studied Left-sided breast cancer (n=10). DIBH-3DCRT and FB-HT vs. FB-3DCRT was evaluated on Radiation dose to cardiac substructures. DIBH-3DCRT and FB-HT significantly reduced the radiation dose to the heart, left anterior descending coronary artery, and ventricles compared to FB-3DCRT.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: